Recombinant Human Sal-Like Protein 4 (SALL4) Protein (His)

Name: Recombinant Human Sal-Like Protein 4 (SALL4) Protein (His)
Brand: Beta LifeScience
SKU: BLC-00038P
Price: 349.0 USD
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Other recombinant proteins, Recombinant proteins, Recombinant proteins holiday sale

Price Save $1,055

Size

100ug

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Sal-Like Protein 4 (SALL4) Protein (His) is produced by our Baculovirus expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	Q9UJQ4
Target Symbol	SALL4
Synonyms	AA407717; AL022809; AW536104; C330011P20Rik; C78083; C78563; dJ1112F19.1; DRRS; HSAL4; Sal like 4 (Drosophila); Sal like 4; Sal like Protein 4; Sal-like protein 4; Sall4; SALL4_HUMAN; Spalt like transcription factor 4; Tex20; Zinc finger protein 797; Zinc finger protein SALL4; ZNF797
Species	Homo sapiens (Human)
Expression System	Baculovirus
Tag	N-10His
Target Protein Sequence	PKEILAPSVNVDPVVWNQYTSMLNGGLAVKTNEISVIQSGGVPTLPVSLGATSVVNNATVSKMDGSQSGISADVEKPSATDGVPKHQFPHFLEENKIAVSRRRRRRRRRRR
Expression Range	954-1053aa+11R
Protein Length	Partial
Mol. Weight	16
Research Area	Developmental Biology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Transcription factor with a key role in the maintenance and self-renewal of embryonic and hematopoietic stem cells.
Subcellular Location	Cytoplasm. Nucleus.
Protein Families	Sal C2H2-type zinc-finger protein family
Database References	HGNC: 15924 OMIM: 147750 KEGG: hsa:57167 STRING: 9606.ENSP00000217086 UniGene: Hs.517113
Associated Diseases	Duane-radial ray syndrome (DRRS); Oculootoradial syndrome (OORS)
Tissue Specificity	Expressed in testis. Constitutively expressed in acute myeloid leukemia (AML).

Gene Functions References

an HBV-pSTAT3-SALL4-miR-200c axis regulates PD-L1 causing T cell exhaustion PMID: 29593314
the TRIM21 knockdown increases SALL1 levels, indicating that TRIM21 degrades both SALL1 and SALL4. PMID: 29511085
These data indicate that aberrantly expressed SALL4 in human choriocarcinoma cells may promote cell proliferation via beta-catenin/c-Myc pathway PMID: 28639477
SALL4 was significantly upregulated in glioma tissues and cell lines, and an inverse correlation between miR-98 and SALL4 expression in glioma tissues was identified. PMID: 29436585
TNFSF13, SPATC1L, SLC22A25 and SALL4 may thus be novel susceptibility loci for atrial fibrillation in the Japanese population PMID: 28849223
Study showed significantly high expression of SALL4 mRNA in glioma specimens as compared to non-tumor samples using RT-PCR. Blocking SALL4 using SALL4-siRNA decreased proliferation of U87 and U251 cells, which was reversed by the addition of PTEN inhibitor phen (bpv). Furthermore, marked increase in PTEN mRNA and protein levels was seen in cells treated with siRNA-SALL4. PMID: 28887597
SALL4 is a promising prognostic biomarker for cancer, and is appropriate for the assessment of cancer prognosis in the Chinese people. PMID: 28582841
Our experimental data indicated that over expression of SALL4 was found in CRC and low expression of SALL4 was connected with high survival rate after surgery. Thus our study suggested that SALL4 could serve as a potential diagnostic and prognostic marker of CRC. PMID: 28869451
SALL4 is a target gene of miR-181b in glioma.SALL4 is upregulated in glioma. PMID: 27938503
SALL4 is a target gene of mir-98 in non-small cell lung cancer cells. PMID: 27938506
miR-98 plays a suppressive role in the proliferation, migration, invasion and EMT of HCC cells, partly at least, via directly inhibition of SALL4. PMID: 27677076
SALL4 immunopositivity is not a prognostic factor in Combined hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) (cHCC-CC); however, it is associated with alpha-fetoprotein, glypican 3 and EpCAM immunopositivity, indicating the mechanism of carcinogenesis. PMID: 26267070
these data suggest that Bmi-1 could serve as a novel prognostic biomarker in pediatric primary acute lymphoblastic leukemia (ALL)and may be partially regulated by Sall4a. Our study also showed that Bmi-1 could serve as a new therapeutic target for the treatment of pediatric ALL. PMID: 28122538
SALL4 overexpression is associated with neoplasms. PMID: 27007163
Findings indicate that long-term exposure to IM results in dysregulation of stem cell renewal-regulatory Hippo (MST1/2)/YAP signaling, and that inhibition of miR-181a using a microRNA sponge inhibitor resulted in decreased transcription of SOX2 and SALL4. PMID: 28103766
Study showed that SALL4 was overexpressed in a majority of human esophageal squamous cell carcinoma (ESCC) tissues and that aberrantly activated SALL4 may contribute to esophageal tumorigenesis by promoting malignant proliferation and inhibiting cell apoptosis, regulating esophageal squamous cell migration, invasion and cell cycle. PMID: 27329034
Data show that SALL4 promotes the expression of Glut1 and open chromatin through a HP1alpha-dependent mechanism. PMID: 28759035
Our report is the first description of structural eye defects associated with two missense variants in SALL4 inherited in trans; the absence of reported findings in both parents suggests that both sequence variants are hypomorphic mutations and that both are needed for the ocular phenotype. PMID: 27661448
our study showed that SALL4 plays an important role in regulating the proliferation, migration, and invasion of osteosarcoma cells. PMID: 27983924
The SALL4 - integrin alpha6 - integrin beta1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. PMID: 27773610
Coexpression of SALL4 with HDAC1 and/or HDAC2 was associated with PTEN underexpression and a poor prognosis in hepatocellular carcinoma. PMID: 28411180
SALL4 has a negative impact in DNA damage repair, and support the model of dual functional properties of SALL4 in leukemogenesis through inhibiting DNA damage repair and promoting cell survival. PMID: 27132514
demethylation of CpGs located within OCT4 and STAT3 cis-acting elements, downstream of SALL4 TSS, enables OCT4 and STAT3 binding, recruitment of BRG1, and enhanced RNA polymerase II elongation and SALL4 transcription PMID: 27797380
SALL4 was expressed in 100% of choriocarcinomas and it was not detected in any placental site trophoblastic tumor and epithelioid trophoblastic tumor. PMID: 27068524
SALL4 is useful for subtyping hepatoblastoma, and high SALL4 expression is associated with decreased survival in hepatoblastoma. PMID: 27252091
expression detected in 36% of undifferentiated/dedifferentiated endometrial carcinomas, not other in high-grade endometrial carcinomas PMID: 28272224
miR33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of SALL4 expression. PMID: 28026002
this study demonstrates that miR-16 plays a suppressive role in regulating cell proliferation, migration and invasion, and EMT in glioma, at least in part by directly targeting SALL4. PMID: 27748823
We evaluate the effects of siRNA-inhibited expression of the SALL4 gene on the proliferation, colony formation, and apoptosis of prostate cancer C4-2 cells. Silencing SALL4 expression by using siRNA technology inhibited the proliferation and colony formation of C4-2 cells, and promoted apoptosis likely mediated by Bcl-2 and Bax expression. PMID: 27323021
the under-expression of SOX1 was associated significantly with SALL4 overexpression. This study was the first to evaluate SOX1 underexpression and its association with poor prognosis in esophageal squamous cell carcinoma. PMID: 27576349
Hepatocellular carcinoma patients with higher expression levels of SALL4 and AFP have worse prognosis. PMID: 26973422
Persistent expression of SALL4 in metastatic MGCTs resistant to chemoradiation also raises the possibility for targeted systemic therapy as the anti-SALL4 peptide continues to be developed PMID: 25906119
SALL4 and beta-catenin were positively correlated in colorectal cancer. PMID: 26779651
SALL4 was highly expressed and correlated with poor prognosis in SOC patients, promoting invasion and metastasis of OC cells. PMID: 26750614
Study reports a novel heterozygous frameshift insertion in SALL4, c.410dupG (p.Gly138Argfs*43) segregating with Okihiro syndrome in a Brazilian pedigree with five affected individuals; the c.410dupG variant in SALL4 gene reported here is the cause of Okihiro syndrome without Duane anomaly, but with foot defect in one affected individual. PMID: 26791099
By inhibition of SALL4 expression, the proliferation, invasiveness and drug resistance were dramatically reduced while apoptosis rate was up-regulated. PMID: 26617716
SALL4 expression in squamous cell carcinoma of the esophagus may constitute a sign of dedifferentiation leading to poor patient prognosis PMID: 26818834
SALL4 has an oncogenic role in intrahepatic cholangiocarcinoma PMID: 26317546
review aims to summarize our current knowledge of SALL4, including a SALL4-based approach to classify and target cancers PMID: 26892498
SALL4 could induce Epithelial-mesenchymal transition and resistance to antineoplastic drugs through the regulation of c-Myc. SALL4 and c-Myc may be novel therapeutic targets for endometrial cancer. PMID: 26407074
The results show that miR-219-5p inhibited carcinogenesis of colon cancer by targeting oncogene Sall4 PMID: 26238082
identifies the KRLR sequence as a bona fide nuclear localization signal for SALL4B. PMID: 24626181
An atypical 0.73 MB microduplication of 22q11.21 and a novel SALL4 missense mutation associated with thumb agenesis and radioulnar synostosis. PMID: 25823593
The mechanism through which miR-33b inhibits the stemness, migration and invasion of breast cancer cells is by targeting HMGA2, SALL4 and Twist1. PMID: 25919570
Results indicate that SALL4 overexpression acts as a natural resistance factor and may be involved in the recurrence of lung cancer after adjuvant chemotherapy. PMID: 25646965
Results indicated that the SALL4 may play an important role in progression, development and maintenance of glioma PMID: 25359397
Despite moderate sensitivity, SALL4 expression may aid in distinguishing Malignant rhabdoid tumours from epithelioid sarcomas PMID: 24827994
Aberrant SALL4 expression has been found in nearly all AML cases, whereas, in normal bone marrow and peripheral blood cells, its expression is only restricted to hematopoietic stem/progenitor cells. PMID: 25737450
the evaluation of ERG and SALL4 immunoexpressions may be a useful diagnostic tool to distinguish epithelioid sarcoma, especially proximal type, from malignant rhabdoid tumor PMID: 25479928
SALL4 has functional roles in metastasis and drug resistance in aggressive endometrial cancer PMID: 24336327

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.